First human test of new 'Living Drug' for Tough-to-Treat cancers
NCT ID NCT06193902
Summary
This early-stage study is testing the safety and finding the right dose of a new personalized cell therapy called LEU011 for adults with advanced solid tumors that have come back or stopped responding to standard treatments. Doctors take a patient's own blood cells, modify them in a lab to target cancer, and give them back as a single infusion after a short course of chemotherapy. The main goal is to see how well patients tolerate the treatment and to monitor for side effects over two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guy's and St Thomas' NHS Foundation Trust
RECRUITINGLondon, SE1 9RT, United Kingdom
Contact
Contact Phone: •••-•••-••••
-
The Christie NHS Foundation Trust
RECRUITINGManchester, M20 4BX, United Kingdom
Contact
Contact
Conditions
Explore the condition pages connected to this study.